Skip to main content
Top
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Iron Deficiency | Research

Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study

Authors: Bertrand Fougère, François Puisieux, Pascal Chevalet, Cédric Annweiler, Emeline Michel, Laure Joly, Frédéric Blanc, Abdelghani EL Azouzi, Valérie Desré-Follet, Patrice Cacoub, on behalf of the CARENFER PA study group*

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Iron deficiency (ID) is often associated with other comorbidities in older patients and is a factor of morbimortality. However, the prevalence of ID remains poorly documented in this population.

Methods

The CARENFER PA study was a French multicenter cross-sectional study whose objective was to evaluate ID in patients (> 75 years) admitted to a geriatric unit. The primary endpoint was the ID prevalence defined as: serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%. The Short Physical Performance Battery (SPPB) test was used to identify older patients at high risk of adverse events (e.g., disability, falls, hospitalization, death).

Results

A total of 888 patients (mean age, 85.2 years; women, 63.5%) from 16 French centers were included from October 2022 to December 2022. The prevalence of ID was 57.6% (95% CI, 54.3–60.9) in the cohort of older patients (62.6% in anemic and 53.3% in non-anemic patients; p = 0.0062). ID prevalence increased significantly with the presence of more than three comorbidities (65.6% vs. 55.9%; p = 0.0274), CRP ≥ 12 mg/L (73.0% vs. 49.3%; p < 0.001) and treatment that may influence ID/anemia (60.5% vs. 49.6%; p = 0.0042). In multivariate analysis, only CRP ≥ 12 mg/L was an independent predictive factor of ID (odds ratio, 2.78; 95% CI, 1.92–4.08; p < 0.001). SPPB scores were low (0–6) in 60.5% of patients with ID versus 48.6% of patients without ID (p = 0.0076).

Conclusion

More than half of older patients had ID, including non-anemic patients. ID was associated with the presence of inflammation and a low SPPB score.

Trial registration

NCT05514951.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–8.PubMedCrossRef Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–8.PubMedCrossRef
4.
go back to reference Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107:3841–6.PubMedCrossRef Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107:3841–6.PubMedCrossRef
7.
go back to reference Cohen-Solal A, Philip JL, Picard F, Delarche N, Taldir G, Gzara H, Korichi A, Trochu JN, Cacoub P, Group CS. Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Fail. 2022;9:874–84.PubMedPubMedCentralCrossRef Cohen-Solal A, Philip JL, Picard F, Delarche N, Taldir G, Gzara H, Korichi A, Trochu JN, Cacoub P, Group CS. Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Fail. 2022;9:874–84.PubMedPubMedCentralCrossRef
8.
go back to reference Choukroun G, Kazes I, Dantal J, Vabret E, Couzi L, Le Meur Y, Trochu JN, Cacoub P. investigateurs de l’etude CI: [Prevalence of iron deficiency in patients with non-dialysis chronic kidney disease: The CARENFER national, multicentre, observational study]. Nephrol Ther. 2022;18:195–201.PubMedCrossRef Choukroun G, Kazes I, Dantal J, Vabret E, Couzi L, Le Meur Y, Trochu JN, Cacoub P. investigateurs de l’etude CI: [Prevalence of iron deficiency in patients with non-dialysis chronic kidney disease: The CARENFER national, multicentre, observational study]. Nephrol Ther. 2022;18:195–201.PubMedCrossRef
9.
go back to reference Peyrin-Biroulet L, Bouguen G, Laharie D, Pellet G, Savoye G, Gilletta C, Michiels C, Buisson A, Fumery M, Trochu JN, et al. Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study. Dig Dis Sci. 2022;67:5637–46.PubMedPubMedCentralCrossRef Peyrin-Biroulet L, Bouguen G, Laharie D, Pellet G, Savoye G, Gilletta C, Michiels C, Buisson A, Fumery M, Trochu JN, et al. Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study. Dig Dis Sci. 2022;67:5637–46.PubMedPubMedCentralCrossRef
10.
go back to reference Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(575–582):e573. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(575–582):e573.
11.
go back to reference Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int. 2019;96:750–60.PubMedCrossRef Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int. 2019;96:750–60.PubMedCrossRef
12.
go back to reference Eisenga MF, Nolte IM, van der Meer P, Bakker SJL, Gaillard C. Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol. 2018;19:225.PubMedPubMedCentralCrossRef Eisenga MF, Nolte IM, van der Meer P, Bakker SJL, Gaillard C. Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol. 2018;19:225.PubMedPubMedCentralCrossRef
13.
go back to reference Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24:1886–92.PubMedPubMedCentralCrossRef Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24:1886–92.PubMedPubMedCentralCrossRef
14.
go back to reference Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleskowska-Florek W, Zymlinski R, Biegus J, Siwolowski P, Banasiak W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35:2468–76.PubMedCrossRef Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleskowska-Florek W, Zymlinski R, Biegus J, Siwolowski P, Banasiak W, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014;35:2468–76.PubMedCrossRef
15.
go back to reference Marinho J, Leao I, Custodio S, Dias E, Moreira Pinto A, Costa T, Capela A, Dias M, Coelho H, Cunha A, et al. Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion. Sci Rep. 2019;9:20410.PubMedPubMedCentralCrossRef Marinho J, Leao I, Custodio S, Dias E, Moreira Pinto A, Costa T, Capela A, Dias M, Coelho H, Cunha A, et al. Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion. Sci Rep. 2019;9:20410.PubMedPubMedCentralCrossRef
16.
go back to reference Aksan A, Isik H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–18.PubMedCrossRef Aksan A, Isik H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303–18.PubMedCrossRef
17.
go back to reference Aksan A, Schoepfer A, Juillerat P, Vavricka S, Bettencourt M. Ramirez de Arellano A, Gavata S, Morin N, Valentine WJ, Hunt B: Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Adv Ther. 2021;38:660–77.PubMedCrossRef Aksan A, Schoepfer A, Juillerat P, Vavricka S, Bettencourt M. Ramirez de Arellano A, Gavata S, Morin N, Valentine WJ, Hunt B: Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Adv Ther. 2021;38:660–77.PubMedCrossRef
18.
go back to reference Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–9.PubMedCrossRef Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–9.PubMedCrossRef
19.
go back to reference Rottembourg J, Sonigo Y, Dansaert A, Diaconita M, Guerin A. Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients. Nephrol Ther. 2013;9:486–93.PubMedCrossRef Rottembourg J, Sonigo Y, Dansaert A, Diaconita M, Guerin A. Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients. Nephrol Ther. 2013;9:486–93.PubMedCrossRef
20.
go back to reference Rottembourg J, Rostoker G. Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice. Nephrol Ther. 2015;11:531–42.PubMedCrossRef Rottembourg J, Rostoker G. Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice. Nephrol Ther. 2015;11:531–42.PubMedCrossRef
21.
go back to reference Rottembourg J. Other Estimation of Blood Losses in Hemodialysis and Formula for Translating Liver Iron Concentration From Iron Balance Calculation Based on Iron Removal by Phlebotomy. Kidney Int Rep. 2018;3:220.PubMedCrossRef Rottembourg J. Other Estimation of Blood Losses in Hemodialysis and Formula for Translating Liver Iron Concentration From Iron Balance Calculation Based on Iron Removal by Phlebotomy. Kidney Int Rep. 2018;3:220.PubMedCrossRef
22.
go back to reference Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.PubMedCrossRef Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.PubMedCrossRef
23.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
24.
go back to reference Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020;31:456–68.PubMedPubMedCentralCrossRef Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020;31:456–68.PubMedPubMedCentralCrossRef
25.
go back to reference Cacoub P, Vandewalle C, Peoc’h K. Using transferrin saturation as a diagnostic criterion for iron deficiency: A systematic review. Crit Rev Clin Lab Sci. 2019;56:526–32.PubMedCrossRef Cacoub P, Vandewalle C, Peoc’h K. Using transferrin saturation as a diagnostic criterion for iron deficiency: A systematic review. Crit Rev Clin Lab Sci. 2019;56:526–32.PubMedCrossRef
26.
go back to reference Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc’h K, Andrieu V, Lasocki S, Puy H, Trochu JN. Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients. 2022;14(5):1039.PubMedPubMedCentralCrossRef Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc’h K, Andrieu V, Lasocki S, Puy H, Trochu JN. Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients. 2022;14(5):1039.PubMedPubMedCentralCrossRef
27.
go back to reference Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102:1585–94.PubMedCrossRef Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102:1585–94.PubMedCrossRef
28.
go back to reference Western MJ, Malkowski OS. Associations of the Short Physical Performance Battery (SPPB) with Adverse Health Outcomes in Older Adults: A 14-Year Follow-Up from the English Longitudinal Study of Ageing (ELSA). Int J Environ Res Public Health. 2022;19(23):16319.PubMedPubMedCentralCrossRef Western MJ, Malkowski OS. Associations of the Short Physical Performance Battery (SPPB) with Adverse Health Outcomes in Older Adults: A 14-Year Follow-Up from the English Longitudinal Study of Ageing (ELSA). Int J Environ Res Public Health. 2022;19(23):16319.PubMedPubMedCentralCrossRef
29.
go back to reference Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-94.PubMedCrossRef Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-94.PubMedCrossRef
30.
go back to reference Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37.
31.
go back to reference Blum LV, Zierentz P, Hof L, Kloka JA, Messroghli L, Zacharowski K, Meybohm P, Choorapoikayil S. The impact of intravenous iron supplementation in elderly patients undergoing major surgery. BMC Geriatr. 2022;22:293.PubMedPubMedCentralCrossRef Blum LV, Zierentz P, Hof L, Kloka JA, Messroghli L, Zacharowski K, Meybohm P, Choorapoikayil S. The impact of intravenous iron supplementation in elderly patients undergoing major surgery. BMC Geriatr. 2022;22:293.PubMedPubMedCentralCrossRef
32.
go back to reference Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, Spahn DR, Orav EJ, Vellas B, da Silva JAP, et al. Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022;34:2205–15.PubMedPubMedCentralCrossRef Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, Spahn DR, Orav EJ, Vellas B, da Silva JAP, et al. Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022;34:2205–15.PubMedPubMedCentralCrossRef
33.
go back to reference Neidlein S, Wirth R, Pourhassan M. Iron deficiency, fatigue and muscle strength and function in older hospitalized patients. Eur J Clin Nutr. 2021;75:456–63.PubMedCrossRef Neidlein S, Wirth R, Pourhassan M. Iron deficiency, fatigue and muscle strength and function in older hospitalized patients. Eur J Clin Nutr. 2021;75:456–63.PubMedCrossRef
34.
go back to reference Philip KEJ, Sadaka AS, Polkey MI, Hopkinson NS, Steptoe A, Fancourt D. The prevalence and associated mortality of non-anaemic iron deficiency in older adults: a 14 years observational cohort study. Br J Haematol. 2020;189:566–72.PubMedPubMedCentralCrossRef Philip KEJ, Sadaka AS, Polkey MI, Hopkinson NS, Steptoe A, Fancourt D. The prevalence and associated mortality of non-anaemic iron deficiency in older adults: a 14 years observational cohort study. Br J Haematol. 2020;189:566–72.PubMedPubMedCentralCrossRef
35.
go back to reference Portugal-Nunes C, Castanho TC, Amorim L, Moreira PS, Mariz J, Marques F, Sousa N, Santos NC, Palha JA. Iron Status is Associated with Mood, Cognition, and Functional Ability in Older Adults: A Cross-Sectional Study. Nutrients. 2020;12(11):3594.PubMedPubMedCentralCrossRef Portugal-Nunes C, Castanho TC, Amorim L, Moreira PS, Mariz J, Marques F, Sousa N, Santos NC, Palha JA. Iron Status is Associated with Mood, Cognition, and Functional Ability in Older Adults: A Cross-Sectional Study. Nutrients. 2020;12(11):3594.PubMedPubMedCentralCrossRef
36.
go back to reference Capdevila X, Lasocki S, Duchalais A, Rigal JC, Mertl P, Ghewy P, Farizon F, Lanz T, Buckert A, Belarbia S, et al. Perioperative Iron Deficiency in Patients Scheduled for Major Elective Surgeries: A French Prospective Multicenter Cross-Sectional Study. Anesth Analg. 2023;137(2):322–31.PubMedCrossRef Capdevila X, Lasocki S, Duchalais A, Rigal JC, Mertl P, Ghewy P, Farizon F, Lanz T, Buckert A, Belarbia S, et al. Perioperative Iron Deficiency in Patients Scheduled for Major Elective Surgeries: A French Prospective Multicenter Cross-Sectional Study. Anesth Analg. 2023;137(2):322–31.PubMedCrossRef
38.
go back to reference Babaei M, Shafiei S, Bijani A, Heidari B, Hosseyni SR, Vakili Sadeghi M. Ability of serum ferritin to diagnose iron deficiency anemia in an elderly cohort. Rev Bras Hematol Hemoter. 2017;39:223–8.PubMedPubMedCentralCrossRef Babaei M, Shafiei S, Bijani A, Heidari B, Hosseyni SR, Vakili Sadeghi M. Ability of serum ferritin to diagnose iron deficiency anemia in an elderly cohort. Rev Bras Hematol Hemoter. 2017;39:223–8.PubMedPubMedCentralCrossRef
39.
go back to reference Holyoake TL, Stott DJ, McKay PJ, Hendry A, MacDonald JB, Lucie NP. Use of plasma ferritin concentration to diagnose iron deficiency in elderly patients. J Clin Pathol. 1993;46:857–60.PubMedPubMedCentralCrossRef Holyoake TL, Stott DJ, McKay PJ, Hendry A, MacDonald JB, Lucie NP. Use of plasma ferritin concentration to diagnose iron deficiency in elderly patients. J Clin Pathol. 1993;46:857–60.PubMedPubMedCentralCrossRef
40.
go back to reference Hanon O, Vidal JS, Pisica-Donose G, Orvoen G, David JP, Chaussade E, Caillard L, de Jong LW, Boulloche N, Vinsonneau U, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107:1376–82.PubMedCrossRef Hanon O, Vidal JS, Pisica-Donose G, Orvoen G, David JP, Chaussade E, Caillard L, de Jong LW, Boulloche N, Vinsonneau U, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107:1376–82.PubMedCrossRef
41.
go back to reference Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008;83:580–8.PubMedCrossRef Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008;83:580–8.PubMedCrossRef
43.
go back to reference Haas JD. Brownlie Tt: Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131:676S-688S.PubMedCrossRef Haas JD. Brownlie Tt: Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131:676S-688S.PubMedCrossRef
Metadata
Title
Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study
Authors
Bertrand Fougère
François Puisieux
Pascal Chevalet
Cédric Annweiler
Emeline Michel
Laure Joly
Frédéric Blanc
Abdelghani EL Azouzi
Valérie Desré-Follet
Patrice Cacoub
on behalf of the CARENFER PA study group*
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-04719-6

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine